Phase 3 Study Update of PA32540 for Prevention of Cardiovascular Disease - MPR

Links shared publicly online about this topic.

  • 0
    total visits

Phase 3 Study Update of PA32540 for Prevention of Cardiovascular Disease - MPR

empr.com

POZEN announced results from two pivotal Phase 3 clinical trials of PA32540, a coordinated-delivery tablet of immediate-release omeprazole (40mg) and delayed release aspirin (325mg) for use for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers.

View full resource at empr.com

Tags: Heart, Heart Disease, Disease and Condition, Phase 3 Clinical Trial, Clinical Trial, Cardiology, disease

  • Share

Most Recently Shared on March 22, 2012 at 3:45 pm By:

Pervasis Provides Update On Progress Of Clinical Program Targeting Peripheral Arterial Disease

medicalnewstoday.com — “Pervasis Therapeutics announced that the first cohort of patients has been fully enrolled in the Phase 1/2 clinical study of PVS-10200, an investigational new drug under development to prevent resView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on June 23, 2010 at 12:37 pm By:

mnt_cardiovasc MNT Cardiovascular Health News

Pervasis Provides Update On Progress Of Clinical Program Targeting Peripheral Arterial Disease http://mnt.to/3Ff9 #cardiovascular

2 years ago...

Advertisement